Abstract:Background: Intravenous aminophylline was the bronchodilator of choice for many years until supplanted by more effective bronchodilators in the treatment of acute paediatric asthma. Recently there has been renewed interest in this therapy for children with acute severe asthma. Objectives: To determine whether addition of intravenous aminophylline produces a beneficial effect in children with acute severe asthma receiving oxygen, maximised inhaled bronchodilators and oral/intravenous glucocorticoids. Search strategy: The Cochrane Airways Group register of trials (based on MEDLINE, EMBASE, CINAHL and hand searched respiratory journals) and reference lists of relevant articles were used to identify relevant studies. The latest search was carried out in October 2000. Selection criteria: Only randomised-controlled trials comparing intravenous aminophylline with placebo in children treated with inhaled bronchodilators and systemic glucocorticoids for acute asthma were considered for this review. Data collection and analysis: Full text of 35 trials were anonymized for author, date and publication and two blinded independent reviewers selected eligible studies for inclusion. Disagreement was resolved through consensus. Seven trials met the inclusion criteria. Attempts were made to contact authors to verify accuracy. Results were reported as weighted mean differences (WMD) or relative risk (RR) with 95% confidential intervals (CI). Main results: Patients in these trials were predominantly school-aged children hospitalised for acute severe asthma with a baseline FEV1 at 35-40% of predicted and/or a baseline Pulmonary Index of 6-7. Aminophylline significantly improved percentage predicted FEV1 by 6 - 8 hours (WMD 8.4%; 95% CI: 0.82, 15.92%). The effect was maintained for 24 hours. Improvements were also seen in symptom scores at 6-8 hours (WMD= -0.71; 95% CI: -0.82,-0.60). There was no reduction in hospital stay or in number of nebulisers required. Vomiting was more likely with aminophylline therapy (Relative Risk = 3.69; 95% CI: 2.15, 6.33). Reviewer's conclusions: Addition of intravenous aminophylline should be considered early in the treatment of children hospitalised with acute severe asthma with sub optimal response to the initial inhaled bronchodilator therapy. Although the improvement is sustained for 24 hours, there is no apparent reduction in length of hospital stay or number of inhaled beta2-agonists nebulisations. Treatment with aminophylline is associated with an increased risk of vomiting.

[Bronchodilating effect of inhalation of aerosolized aminophylline in asthmatic patients]

Early administration of two intravenous bolus of aminophylline added to the standard treatment of children with acute asthma

Efficacy of aminophylline in the treatment of acute asthma exacerbation in children

Intravenous aminophylline for acute severe asthma in children over 2 years using inhaled bronchodilators

Doxofylline versus aminophylline for pediatric acute bronchial asthma and their effects on recurrence

Aminophylline Relieves Asthma Through Inhibiting Eotaxin Expression in Rat Lungs

Modulatory Effect of Aminophylline on the Cytokine Excreted by TH of Asthmatic Children During Remission Period.

Efficacy and usability of a novel nebulizer targeting both upper and lower airways

Aminophylline and the respiratory muscles: an alternative view

Small-Airway Function Variables in Spirometry, Fractional Exhaled Nitric Oxide, and Circulating Eosinophils Predicted Airway Hyperresponsiveness in Patients with Mild Asthma.

Delivery of Aerosolized Bronchodilators by High-Flow Nasal Cannula During COPD Exacerbation

Effect of aminophy1line aerosol on airway mucoea of normal and asthmatic guinea pigs

Safety and Effectivity of Hypertonic Saline on Sputum Induction in Patients with Asthma and Chronic Obstructive Pulmonary Disease

Theophylline does not shorten hospital stay for children admitted for asthma

Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis

1134 A comparison of the aerogen vibrating mesh nebuliser versus a standard jet nebuliser to deliver bronchodilators in moderate to severe asthma in the emergency department

High-flow nasal cannula and in-line aerosolised bronchodilator delivery during severe exacerbation of asthma in adults: a feasibility observational study

Sympathomimetics in acute severe asthma: inhaled or parenteral, nebulizer or spacer?

Evaluation of different nebulized bronchodilators on clinical efficacy and hypokalemia in asthmatic children

Aerosol delivery in lung disease

Pharmacologic modulation of spontaneous histamine release